Alcohol-use disorder is a major public health issue. The current gold standard for the prevention and treatment of the alcohol withdrawal syndrome is diazepam, a GABA-A agonist. Because of side effects like high sedation, risk of respiratory depression, addictive properties and liver impairment, an alternative pharmacological treatment option is desirable. Baclofen is a GABA-B agonist, prescribed for the treatment of spasticity. More recently, it’s off label use has found its place in the management of alcohol-use disorder because of its anti-craving properties. Given its effects on the GABA system and it lacking the negative aspects of diazepam, baclofen could be a viable treatment alternative in managing alcohol withdrawal. This controlled study investigates two dose levels of baclofen (30 and 60 mg/day) compared to diazepam in patients seeking treatment for alcohol withdrawal.
Om de beste ervaringen te bieden, gebruiken we technologieën zoals cookies om apparaat informatie op te slaan en/of te openen. Door toestemming te geven voor deze technologieën kunnen we gegevens verwerken zoals browsegedrag of unieke ID's op deze site. Geen toestemming geven of de toestemming intrekken kan een negatieve invloed hebben op bepaalde functies en mogelijkheden.